SPOTLIGHT -
Dr. Thigpen on Ovarian Cancer Drugs Not Approved by FDA
James "Tate" T. Thigpen, MD, professor of medicine, director of medical oncology, University of Mississippi School of Medicine, discusses the use of agents in ovarian cancer that are not approved by the FDA.
Read More
Dr. Thigpen on Comparing Treatments in Ovarian Cancer
James "Tate" T. Thigpen, MD, Professor of Medicine, Director, Division of Medical Oncology, University of Mississippi School of Medicine, discusses the comparison of treatment options in ovarian cancer.
Dr Berkenstock on ADC-Related Ocular Toxicities in Cervical and Ovarian Cancers
Dr Matalonis on the Management of Mirvetuximab Soravtansine-Related Toxicities in FRα+ Ovarian Cancer
Updated EMPOWER-Lung 3 Data Support Frontline Cemiplimab Plus Chemo in Advanced NSCLC
Neoadjuvant Nivolumab Plus Chemotherapy Retains EFS Advantage in Resectable NSCLC